How Semaglutide May Protect the Brain: Review of the Diabetes-Alzheimer's Connection and GLP-1 Neuroprotection | Research

The takeaway

This review examines the molecular mechanisms linking type 2 diabetes and Alzheimer's disease and describes semaglutide's neuroprotective potential — including preventing neuronal death, inhibiting amyloid-beta accumulation, and reducing tau hyperphosphorylation.

Limited semaglutide-specific data
Despite being the most prescribed GLP-1 drug, semaglutide has had surprisingly few focused neuroprotection studies — most evidence is extrapolated from older drugs like liraglutide, creating an urgent research gap.

What the researchers found

The review identifies the molecular connections between type 2 diabetes and Alzheimer's disease:

- Impaired brain insulin signaling leads to neuronal degeneration and reduced synaptic activity

- GLP-1 naturally plays a role in brain glucose control and insulin signaling

- GLP-1 receptor agonists demonstrate neuroprotective properties including: prevention of neuronal death, inhibition of amyloid-beta (Aβ) accumulation, and mitigation of tau hyperphosphorylation

- Semaglutide, despite being the most widely used GLP-1RA, has had limited focused neuroprotection studies compared to older GLP-1 drugs like liraglutide and exenatide

The review calls for more semaglutide-specific research given its unique pharmacological properties (longer half-life, higher potency) compared to earlier GLP-1 drugs.

Why it matters

With semaglutide prescribed to tens of millions of people, understanding its brain effects is critical. Alzheimer's disease affects over 55 million people worldwide, and there is growing evidence that GLP-1 drugs provide neuroprotection beyond their metabolic benefits. Semaglutide is currently in clinical trials for Alzheimer's (the EVOKE and EVOKE+ trials), and this review provides the mechanistic framework for understanding why these trials were initiated and what outcomes to expect.

How the study worked

This is a narrative review examining the literature on molecular mechanisms linking Alzheimer's disease and type 2 diabetes, the neuroprotective properties of GLP-1 receptor agonists, and specifically the limited evidence on semaglutide's brain effects.

What this study cannot tell us

This is a narrative review, not a systematic review, so the literature coverage may not be comprehensive. The neuroprotective evidence for semaglutide is largely extrapolated from studies of other GLP-1 drugs (liraglutide, exenatide), and semaglutide-specific brain data is limited. The review does not discuss the EVOKE/EVOKE+ clinical trial results (which may not have been available). Animal model findings may not translate to human Alzheimer's disease. The blood-brain barrier penetration of semaglutide and its direct versus indirect brain effects remain debated.

How to read the evidence

This is a narrative review synthesizing preclinical and mechanistic evidence. It provides a useful overview of the diabetes-Alzheimer's molecular link and GLP-1 neuroprotection but does not include new data or systematic evidence assessment.

When this study was published

Published in 2025, this review is current and timely given the ongoing EVOKE/EVOKE+ clinical trials of semaglutide for Alzheimer's disease.

The bigger picture

The concept of Alzheimer's as 'type 3 diabetes' has gained traction over the past two decades, with epidemiological data showing diabetic patients have approximately double the risk of developing Alzheimer's. GLP-1 drugs represent a logical therapeutic bridge between these conditions. With semaglutide now in Phase 3 Alzheimer's trials (EVOKE/EVOKE+), this review is timely in synthesizing the preclinical rationale. If semaglutide proves effective for Alzheimer's, it would represent one of the most significant drug repurposing achievements in medical history.

Questions still open

Will the EVOKE/EVOKE+ Phase 3 trials of semaglutide in early Alzheimer's show clinically meaningful cognitive benefit?
Does semaglutide's longer half-life and higher GLP-1R affinity translate to superior neuroprotection compared to liraglutide?
Could oral semaglutide achieve sufficient brain exposure for neuroprotection, or is subcutaneous delivery necessary?

Common questions

Could semaglutide prevent or treat Alzheimer's disease?

There's growing evidence it might help. Semaglutide activates GLP-1 receptors in the brain, which can restore insulin signaling, protect neurons from dying, and reduce the buildup of toxic proteins (amyloid and tau) associated with Alzheimer's. Large clinical trials (EVOKE and EVOKE+) are currently testing semaglutide in people with early Alzheimer's. Results are expected to provide definitive answers.

What's the connection between diabetes and Alzheimer's disease?

Both conditions involve problems with insulin. In diabetes, the body struggles to use insulin for blood sugar control. In Alzheimer's, brain cells become insulin resistant, losing their energy supply and ability to clear toxic proteins. People with type 2 diabetes have about twice the risk of developing Alzheimer's. GLP-1 drugs like semaglutide may help by restoring brain insulin signaling, essentially treating both conditions' underlying metabolic dysfunction.

Read the original research

Neuroprotective Role of the Novel GLP-1R Agonist Semaglutide.

Current medicinal chemistry

View on PubMed ↗Publisher’s paper ↗

Citation

Kenzheshova, Akniyet; Moldasheva, Aiman; Aljofan, Mohamad. (2025). Neuroprotective Role of the Novel GLP-1R Agonist Semaglutide.. Current medicinal chemistry. https://doi.org/10.2174/0109298673359635250401051339